COST-EFFECTIVENESS OF TREMELIMUMAB PLUS DURVALUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA IN THE UNITED STATES

被引：0
|
作者：
Xiong, X. [1 ]
Guo, J. J. [2 ]
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
[2] Univ Cincinnati, Plain City, OH USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE520
引用
收藏
页码：S152 / S152
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
    Shu, Yamin
    Tang, Ying
    Ding, Yufeng
    Zhang, Qilin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 122
  • [42] Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma
    Tseng, Chien-Yu
    Tsai, Yi-Wen
    Shiu, Ming-Neng
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [43] A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
    Abou-Alfa, Ghassan K.
    Chan, Stephen Lam
    Furuse, Junji
    Galle, Peter R.
    Kelley, Robin Kate
    Qin, Shukui
    Armstrong, Jon
    Darilay, Annie
    Vlahovic, Gordana
    Negro, Alejandra
    Sangro, Bruno
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] An open-label, multi-center phase IIIb study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma (TREMENDOUS study).
    Fan, Jia
    Qin, Shukui
    Sun, Hui-Chuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS628 - TPS628
  • [45] FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma
    Patel, Timil H.
    Brewer, Jamie R.
    Fan, Jiaxin
    Cheng, Joyce
    Shen, Yuan-Li
    Xiang, Yue
    Zhao, Hong
    Lemery, Steven J.
    Pazdur, Richard
    Kluetz, Paul G.
    Fashoyin-Aje, Lola A.
    CLINICAL CANCER RESEARCH, 2024, 30 (02) : 269 - 273
  • [46] COST-EFFECTIVENESS OF CETUXIMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN THE UNITED STATES
    Ortendahl, J. D.
    Bentley, T. G.
    Anene, A. M.
    Purdum, A. G.
    Bolinder, B.
    VALUE IN HEALTH, 2014, 17 (03) : A86 - A86
  • [47] Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States
    Shankaran, Veena
    Ortendahl, Jesse D.
    Purdum, Anna G.
    Bolinder, Bjorn
    Anene, Ayanna M.
    Sun, Gordon H.
    Bentley, Tanya G. K.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 65 - 72
  • [48] COST-EFFECTIVENESS OF EFAVIRENZ VERSUS RILPIVIRINE IN HIV PATIENTS INITIATING FIRST-LINE TREATMENT IN THE UNITED STATES
    Bonafede, M.
    Juday, T.
    Lenhart, G.
    Pan, K.
    Hebden, T.
    Correll, T.
    VALUE IN HEALTH, 2012, 15 (04) : A241 - A241
  • [49] The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
    Meng, Rui
    Cao, Yingdan
    Zhou, Ting
    Hu, Hongfei
    Qiu, Yijin
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [50] First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
    Liu Yang
    Xiaobing Song
    Wanxian Zeng
    Zhiwei Zheng
    Wenqiang Lin
    Orphanet Journal of Rare Diseases, 18
12345